{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:29:26Z","timestamp":1777858166943,"version":"3.51.4"},"reference-count":23,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2003,9,1]],"date-time":"2003-09-01T00:00:00Z","timestamp":1062374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2003,9]]},"abstract":"<jats:p>Despite the widespread application of combined selective serotonin reuptake inhibitors (SSRI) and benzodiazepine treatment for panic disorder, there has been relatively little systematic assessment of the safety and efficacy of this therapeutic strategy. Although the limited number of studies to date suggest a more rapid onset of benefit with combined treatment, this study is the first to address the critical question of whether continued combined treatment confers superior efficacy. This study is a randomized, double-blind, three-arm study in patients with panic disorder (n = 60), comparing the efficacy and safety of paroxetine and placebo (PP), paroxetine coadministered with clonazepam followed by a tapered benzodiazepine discontinuation phase (PC-D), and ongoing combination treatment (PC-M). All treatment groups demonstrated significant improvement by endpoint. There was a significant advantage for the combined treatment groups early in treatment but, subsequently, outcome in all three groups was similar. A trend towards greater achievement of endpoint remission status for the PC-D group was attenuated when variability in baseline severity was considered. The results of this study should be interpreted in the context of a relatively moderate sample size and higher rates of early dropout. Combined treatment with paroxetine and clonazepam resulted in more rapid response than with the SSRI alone, but there was no differential benefit beyond the initial few weeks of therapy. Initiating combined treatment followed by benzodiazepine taper after a few weeks may provide early benefit while avoiding the potential adverse consequences of long-term combination therapy.<\/jats:p>","DOI":"10.1177\/02698811030173009","type":"journal-article","created":{"date-parts":[[2003,9,25]],"date-time":"2003-09-25T16:10:51Z","timestamp":1064506251000},"page":"276-282","source":"Crossref","is-referenced-by-count":91,"title":["Combined Paroxetine and Clonazepam Treatment Strategies Compared to                Paroxetine Monotherapy for Panic Disorder"],"prefix":"10.1177","volume":"17","author":[{"given":"Mark H.","family":"Pollack","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Massachusetts General Hospital, and Harvard                        Medical School, Boston, MA, USA,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi M.","family":"Simon","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Massachusetts General Hospital, and Harvard                        Medical School, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J.","family":"Worthington","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Massachusetts General Hospital, and Harvard                        Medical School, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia L.","family":"Doyle","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Massachusetts General Hospital, and Harvard                        Medical School, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Peters","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Massachusetts General Hospital, and Harvard                        Medical School, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fany","family":"Toshkov","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Massachusetts General Hospital, and Harvard                        Medical School, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael W.","family":"Otto","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Massachusetts General Hospital, and Harvard                        Medical School, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2003,9,1]]},"reference":[{"key":"atypb1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.155.1.1"},{"key":"atypb2","unstructured":"Dannon P N, Iancu I, Grunhaus L J (1999) Short-term potentiation of paroxetine with clonazepam in the treatment of patients with panic disorder , pp. 153 . American Psychiatric Association Annual Meeting. Washington, DC"},{"key":"atypb3","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.146.2.283"},{"key":"atypb4","doi-asserted-by":"crossref","unstructured":"First M B, Spitzer R L, Gibbon M, Williams J B (1996) Structured Clinical Interview for DSM-IV Axis I Disorders, patient edn. Biometrics Research Department, New York","DOI":"10.1037\/t07827-000"},{"key":"atypb5","unstructured":"Glass G V, McGraw B, Smith M L (1980) Meta-analysis in social research. Sage Publications, Newbury Park, CA"},{"key":"atypb6","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.58.7.681"},{"key":"atypb7","doi-asserted-by":"crossref","unstructured":"Goldstein S (1986) Sequential treatment of panic disorder with alprazolam and Imipramine . Am J Psychiatry 143: 1634","DOI":"10.1176\/ajp.143.12.1634b"},{"key":"atypb8","unstructured":"Guy W (1976) Assessment manual for psychopharmacology. US Government Printing Office, Washington, DC"},{"key":"atypb9","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8341.1959.tb00467.x"},{"key":"atypb10","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.23.1.56"},{"key":"atypb11","unstructured":"Jobson K O, Davidson J, Lydiard R B, McAnn U, Pollack M H, Rosenbaum J F (1995) Algorithm for the treatment of panic disorder with agoraphobia . Psychopharm Bull 31: 457-507"},{"key":"atypb12","doi-asserted-by":"publisher","DOI":"10.1007\/BF00788510"},{"key":"atypb13","unstructured":"Otto M W, Pollack M H, Penava S, Maki K (1997) The costs and benefits of cognitive-behavioral and pharmacologic treatments for panic disorder . Twenty-Seventh Congress of European Association for Behavioral Cognitive Therapies, Venice, Italy"},{"key":"atypb14","unstructured":"Physician Drug & Diagnosis Audit (PDDA) (1997) Scott Levin, a division of PMSI"},{"key":"atypb15","unstructured":"Pollack M H, Otto M W, Rosenbaum J F, Sachs G S, O'Neill C, Asher R, Meltzer-Brody S (1990) The longitudinal course of panic disorder. Findings from the MGH naturalistic study . J Clin Psychiatry 51 (Suppl A): 12-16"},{"key":"atypb16","unstructured":"Rickels K, Case W G, Schweizer E, Garcia-Espana F, Fridman R (1990) Benzodiazepine dependence: management of discontinuation . Psychopharm Bull 26: 63-68"},{"key":"atypb17","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1993.01820130067010"},{"key":"atypb18","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.154.11.1571"},{"key":"atypb19","unstructured":"Sheehan D V (1983) The Anxiety Disease. Scribner, New York"},{"key":"atypb20","doi-asserted-by":"crossref","unstructured":"Simon N M, Pollack M H (2000) The current status of the treatment of panic disorder: pharmacotherapy and cognitive-behavioral therapy . Psychiatr Ann 30: 11","DOI":"10.3928\/0048-5713-20001101-06"},{"key":"atypb21","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(01)00359-7"},{"key":"atypb22","doi-asserted-by":"publisher","DOI":"10.1038\/npp.1994.63"},{"key":"atypb23","doi-asserted-by":"crossref","unstructured":"Woods S W, Nagy L M, Koleszar A S, Krystal J H, Heninger G R, Charney D S (1992) Controlled trial of alprazolam supplementation during imipramine treatment of panic disorder . J Clin Psychopharmacol 12: 32-38","DOI":"10.1097\/00004714-199202000-00006"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811030173009","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811030173009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:08:45Z","timestamp":1777507725000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811030173009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,9]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,9]]}},"alternative-id":["10.1177\/02698811030173009"],"URL":"https:\/\/doi.org\/10.1177\/02698811030173009","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,9]]}}}